Two San Diego companies, Cypher Genomics Inc. and Sequenom Inc., announced an agreement to further develop next-generation noninvasive prenatal tests.

Through this agreement, Sequenom, a molecular diagnostics company, will use Cypher's genome interpretation technology, Mantis, to advance analysis of fetal sub-chromosomal variants detected in maternal blood. Often not detected until after birth, sub-chromosomal variants are associated with significant risks of morbidity and mortality.